Icon

INVOKAMET (nda204353)- (50MG;500MG,50MG;1GM,150MG;500MG,150MG;1GM)

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE JANSSEN PHARMS
50MG;500MG,50MG;1GM,150MG;500MG,150MG;1GM
Yes Yes
2030-Jul-06 2018-Mar-29
None None
None No
INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated:  as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus  Canagliflozin is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease  Canagliflozin is indicated to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria.
0 5 0
Total Other Developers 9
Drugs with Suitability No
50MG;500MG ** ** - - -
50MG;1GM ** ** Up - -
150MG;500MG ** ** Up - -
150MG;1GM ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.